Compare GDHG & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GDHG | NEUP |
|---|---|---|
| Founded | 2008 | 1996 |
| Country | China | United States |
| Employees | N/A | 8 |
| Industry | Services-Misc. Amusement & Recreation | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.1M | 28.7M |
| IPO Year | 2022 | N/A |
| Metric | GDHG | NEUP |
|---|---|---|
| Price | $1.77 | $4.43 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $21.00 |
| AVG Volume (30 Days) | 4.4K | ★ 50.5K |
| Earning Date | 07-11-2025 | 05-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.16 | $3.65 |
| 52 Week High | $8.69 | $21.31 |
| Indicator | GDHG | NEUP |
|---|---|---|
| Relative Strength Index (RSI) | 40.04 | 34.68 |
| Support Level | $1.53 | $3.91 |
| Resistance Level | $1.98 | $4.56 |
| Average True Range (ATR) | 0.17 | 0.32 |
| MACD | -0.01 | -0.09 |
| Stochastic Oscillator | 9.52 | 3.45 |
Golden Heaven Group Holdings Ltd is an offshore holding company. Through the operating entities in China, it manages and operates six properties consisting of amusement parks, water parks, and complementary recreational facilities. The parks offer a broad selection of exhilarating and recreational experiences, including both thrilling and family-friendly rides, water attractions, gourmet festivals, circus performances, and high-tech facilities. The firm's revenue is generated from selling access to rides and attractions, charging fees for special event rentals, and collecting regular rental payments from commercial tenants. it opearts in the Cayman Islands, PRC, BVI, and HK.
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.